US Patent 11389511 Controlled-release CNP agonists with reduced side-effects
Patent 11389511 was granted and assigned to Ascendis Pharma on July, 2022 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 11389511 Controlled-release CNP agonists with reduced side-effects
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
